Researcher comment: AMG 510 for KRAS mutation-positive NSCLC | Ramaswamy Govindan

Presenting author Ramaswamy Govindan outlines the key findings of the non-small-cell lung cancer cohort of the phase I trial of the novel KRAS inhibitor AMG 510, and comments on the next steps for the research.